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In a preceding paper [(1987) Nucleic Acids Res. 15, 5787-58011, we have used frans-diamminedichloroplatinum (II) to 
induce reversible RNA-protein crosslinks within the ternary EF-Tu/GTP/Phe-tRNAPhe complex and have identified two 
crosslinking sites on the tRNA. The aim of the present paper is to determine the crosslinking sites on EF-Tu. Two tryptic 
peptides located in domain I could be identified, a major one (residues 45-74) and a minor one (residues 117-154). The 
use of Staphylococcus aureus V8 protease led to the isolation of two major peptides (residues 56-68 and 6468) and one 
minor peptide (118-124). These results are discussed in the light of the current knowledge of the topography of the 
EF-Tu/tRNA complex. 
Elongation factor EF-Tu; tRNA; Reversible crosslinking 
1. INTRODUCTION 
In the protein biosynthesis process, elongation 
factor EF-Tu promotes the binding of the 
aminoacyl-tRNAs to the ribosomal A site. Forma- 
tion of the ternary EF-Tu/GTP/aminoacyl-tRNA 
complex is a prerequisite for this reaction. 
Understanding of the molecular mechanism of 
polypeptide elongation requires detailed knowl- 
edge of the specificity of the ternary complex for- 
mation and of the conformation of the protein and 
tRNA molecules within the complex. To determine 
how EF-Tu interacts with the tRNA, two general 
approaches have been employed. In the first one, 
amino acid residues that are in contact with the 
tRNA within the ternary complex are identified by 
selective amino acid modification: e.g. the binding 
Correspondence address: J. Reinbolt, Laboratoire de 
Biochimie, Institut de Biologie Moltculaire et Cellulaire du 
CNRS, 15, rue RenC Descartes, 67084 Strasbourg Cedex, 
France 
of L-1-tosylamido-2-phenylethylchloromethylke- 
tone (TPCK) to cysteine 81 prevents the interaction 
of EF-Tu with the aminoacyl-tRNA [l]; histidines 
66 and 118 become protected by the aminoacyl- 
tRNA from photooxidation [2,3] and lysines 2, 4, 
237, 248, 263 and 282 at their c-amino group from 
labeling with ethylacetimidate [4]. In the second 
approach, specific crosslinks between EF-Tu and 
the aminoacyl-tRNA are generated within the ter- 
nary complex. So far, only two successful cross- 
linking experiments were reported: one takes place 
through histidine 66 and the amino acid residue of 
w-bromoacetyllysyl-tRNA [5], the other through 
lysines 208 and 237 and the periodate-oxidized 
tRNA in the presence of kirromycin [6,7]. 
Recently, the use of trans-diamminedichloropla- 
tinum (II) (trans-DDP) as a reversible crosslinking 
agent has been developed in our laboratory and 
has been applied to promote RNA-protein cross- 
links in the ribosome [8-lo] and in aminoacyl- 
tRNA synthetase/tRNA complexes [8]. In 
previous work, Wikman et al. [l l] have used trans- 
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DDP to induce specific crosslinks within the ter- 
nary EF-Tu/GTP/Phe-tRNAPh” complex at a suf- 
ficient yield to isolate the coordinated complex and 
to identify two tRNA regions crosslinked to EF- 
Tu: a major one located in the 3’-part of the T- 
stem and a minor one in the 3 ‘-strand of the an- 
ticodon stem. In the present study, we focused on 
the characterization of the regions of EF-Tu 
crosslinked to Phe-tRNAPhe. 
2. MATERIALS AND METHODS 
2.1. Chemicals and biochemicals 
Phosphoenolpyruvate (PEP), dithioerythritol (DTE) and 
trans-diamminedichloroplatinum(l1) (trans-DDP) were from 
Sigma (USA). ATP, GTP , 1 -0octyl-,&D-glucopyranoside 
(OGP), pyruvate kinase (EC 2.7.1.40) and Staphylococcus 
aureus V8 protease (EC 3.4.21.19) were from Boehringer 
(France). Chymotrypsin (EC 3.4.21.1), RNase A (EC 3.1.27.5) 
and TPCK-treated trypsin (EC 3.4.21.4) further purified from 
contaminating nucleases [ 121 were from Worthington 
Biochemical Corp. (USA). AcA 44 gel was from LKB (Sweden), 
Fractogel TSK DEAE-650 (M) from Merck (France) and 
DEAE-cellulose from Whatman (England). All other reagents 
(analytical grade) were from Merck (France) except those 
employed for the sequencer and PICO’TAG systems, which 
were from Applied Biosystems and Waters (USA), respectively. 
We have purified EF-Tu/GDP from a crude Escherichia coli 
(IBPC 5421) extract by chromatographies on DEAE-cellulose 
and AcA 44 as described in [13]. Purified EF-Tu exhibited a 
single band on SDS-polyacrylamide gel electrophoresis (results 
not shown). A specific activity of 20000 U/mg was determined 
by the GDP-exchange assay [14]. Brewer’s yeast tRNAPhc was 
purified by counter current distribution and chromatography 
on BD-cellulose [ 151. Yeast phenylalanyl-tRNA synthetase was 
purified as in [16]. 
2.2. Ternary complex formation and crosslinking 
To convert EF-Tu/GDP in EF-Tu/GTP, 12 nmol of EF- 
Tu/GDP was incubated in 50 pl of buffer A (50 mM Tris-HCl, 
pH 7.5; 10 mM MgClz; 150 mM N&Cl; 0.02 mM 
2-mercaptoethanol; 0.005% OGP) with 30 pg pyruvate kinase, 
1 mM GTP and 40 mM PEP, for 20 min at 37’C. Aminoacyla- 
tion of 150 pg (6 nmol) tRNAPhc was done in 100 pl of buffer 
A containing 160/tM [%]phenylalanine, 2 mM ATP and 
1Opg phenylalanyl-tRNA synthetase for 6 min at 37°C. The 
ternary EF-Tu/GTP/[i4C]Phe-tRNAPhe complex was achieved 
by incubating EF-Tu/GTP and Phe-tRNAPhe , for 2 min at 
37”C, then 20 min on ice. The ternary complex was isolated by 
HPLC with a Waters chromatograph (ALC/GPC-204) using a 
TSK G2000 SW (7.5 x 600 mm) column (LKB-Produkter, 
Sweden). Elution was with buffer B (12.5 mM potassium 
phosphate, pH 7.2; 0.005% OGP) at a flow rate of 0.4 ml/min. 
1 min fractions were collected and those containing the ternary 
complex were pooled. 
Crosslinking was performed by incubating the ternary com- 
plex with a freshly prepared tratrs-DDP (0.35 mM final concen- 
tration) for 1 _h at room temperature in the dark. A final 
concentration of 0.05% OGP and 0.15 M NaCl was then add- 
ed. The crosslinked complexes were fractionated from the non- 
crosslinked species by chromatography on a Fractogel TSK 
DEAE-650 (M) column (3OO,&packed in a Pasteur pipette). 
Elution was at a flow rate of 0.4 ml/min with 12.5 mM 
potassium phosphate, pH 7.2, 0.05% OGP, in the presence of 
increasing concentrations of NaCl as described in [ll]. 1 min 
fractions were collected. 
2.3. Analysis of the crosslinked peptides 
In order to remove NaCl from the sample, the crosslinked 
complex was rechromatographed on a TSK G2000 SW column 
and eluted with 12.5 mM potassium phosphate, pH 7.2, 0.05% 
OGP. Digestion with RNase-free trypsin or Staphylococcus 
aureus V8 protease was achieved in the dark at 20°C (en- 
zyme : substrate ratio of 1: 20 by weight) for 6 h. The digest was 
chromatographed on a TSK G2OOO SW column under the same 
conditions as just described. The peak coeluting with the tRNA 
was pooled and the crosslinks were reversed by a 1 h treatment 
with 20 mM DTE at room temperature. Liberated peptides 
were fractionated on a TSK G2000 SW column as indicated 
above. The tryptic peptides were then dried, dissolved in 10% 
acetic acid for 2 h at room temperature and evaporated again 
to dryness. Chymotryptic digestion of the tryptic peptides was 
performed in 12.5 mM potassium phosphate, pH 7.2, 0.05% 
OGP for 16 h at 37°C (enzyme:substrate ratio of 1:20 by 
weight). 
Amino acid analysis of the released peptides was done with 
the socalled PICO.TAG method. Acid hydrolysis was ac- 
complished in vapors of 6 M HCl at 110°C for 18 h and 
phenylisothiocyanate (PITC) precolumn derivatization pro- 
cedure was performed according to Waters recipe. The 
phenylthiocarbamyl-amino acids (PTC) were analyzed by 
chromatography on a PICO.TAG column (3.9 x 150 mm). 
Peptides were subjected to automated N-terminal degrada- 
tion with PITC on an Applied Biosystems 470 A sequencer. 
Samples were applied to a polybrene-treated and precyclated 
glass-fiber filtre. Amino acid phenylthiohydantoins (PTH) were 
identified by chromatography on a Cl8 column Brownlee (2.1 
x 200 mm) coupled with the 120 A PTH-analyzer, according to 
Applied Biosystems chromatographic parameters. 
3. RESULTS AND DISCUSSION 
fruns-DDP has a square planar geometry where 
the two chlorines span a 7 A long distance. As 
described in detail by Tukalo et al. [8], these 
chlorines can easily be substituted by stronger 
nucleophilic groups. Binding positions are specific: 
on RNA, platinum mainly binds by coordination 
to position N7 of guanines and to a smaller extent 
to Nl of adenines and N3 of cytosines. On the pro- 
tein side, at neutral pH, trans-DDP coordinates to 
the unprotonated nitrogen atoms of the imidazole 
ring of histidines and to the sulphur atom of cys- 
teines and methionines. These crosslinks can either 
be kept stable or can easily be reversed by the addi- 
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tion of stronger nucleophilic groups such as DTE. 
Crosslinks induced by trans-DDP within the ter- 
nary EF-Tu/GTP/Phe-tRNAPhe were achieved 
under the conditions described in a previous work 
[ 111. Under these conditions, an average percen- 
tage of 35 to 40% of the complex could be con- 
verted into crosslinked species. The specificity of 
the crosslinking reaction was also tested as de- 
scribed in detail in the above mentioned work: 
after the platination reaction, the non-crosslinked 
complex was dissociated in the presence of 0.5 M 
NaCl prior to the addition of a large excess of 
[ 14C]Phe-tRNAPhe; elimination of the salt and ap- 
propriate incubation led to the recovery of a 1: 1 
EF-Tu/tRNA complex, indicating that the tRNA 
was crosslinked at its specific site. 
In order to identify the regions of the protein in- 
volved in the crosslinking reaction, the. ternary 
complex was formed as described in the ex- 
perimental section prior to the platination experi- 
ment. The non-crosslinked complex was then 
dissociated in the presence of NaCl and the 
crosslinked EF-Tu/tRNA complex was frac- 
tionated (see section 2). The crosslinked complex 
was then subjected to tryptic digestion and the 
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resulting crosslinked tRNA-peptide complexes 
were separated from unbound peptides by 
chromatography on a TSK G2000 SW column 
(fig.1). Two peaks could be obtained: peak 1 con- 
taining the crosslinked complex as shown by the 
measure of the tRNA radioactivity, and peak 2 
containing the unbound peptides. A Staphylococ- 
cus aureus V8 protease digestion yielded an iden- 
tical profile (result not shown). In order to insure 
that no contaminating peptidic material was 
coeluted with the tRNA, a control experiment was 
performed in which an EF-Tu digest was 
cochromatographed with tRNA under the same 
conditions. In that experiment, no peptides could 
be isolated from the tRNA peak, showing that the 
peptides present in the tRNA peak after platina- 
tion only correspond to the crosslinked peptides. 
The crosslinks were then reversed by treatment 
with DTE and the resulting peptides re- 
chromatographed under the same conditions as 
above. Again, two peaks were isolated, one con- 
taining the radioactive tRNA, the other one con- 
taining the released peptides. The tRNA fractions 
were subjected to an amino acid analysis as 
described in section 2 in order to insure that the 
Pl 
P2 
I 1 
: 
I 
I ’ 
I ’ 
I 
I 
I 
I 4 
4 I 
I 1 
I 
FRACTION NUMBER 
Fig.1. Fractionation of the crosslinked tRNA-peptides complexes by chromatography on a TSK G2000 SW column. 
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crosslinks were completely reversed. From the 
knowledge of the complete amino acid sequence of 
EF-Tu [17], the determination of the amino acid 
composition of the released peptides and 
automated Edman degradation strongly suggested 
that two tryptic peptides could be characterized, a 
major one Ta (78%) encompassing residues 45-74, 
and a minor one Tb (22%) containing residues 
117-154 (fig.2). However, the quantitative 
recovery of PTH-amino acids was very low in- 
dicating that Edman degradation did not proceed 
easily. Indeed, only residues 45-53 of peptide Ta 
could be sequenced unambiguously, whereas Ed- 
man degradation did not go over the N-terminal 
Glu 117 of peptide Tb. This difficulty in sequence 
analysis, often due to the configuration of the pep- 
tides themselves, could be overcome by dissolving 
the above tryptic peptides in 10% acetic acid, dry- 
ing and further subjecting them to a chymotryptic 
digestion in the appropriate buffer. Unambiguous 
sequencing of the resultant smaller chymotryptic 
peptides indicates that they belong to the two tryp- 
tic fragments Ta (45-74) and Tb (117-154) (see 
fig.2). Furthermore, four peptide bonds including 
a basic amino acid were resistant to tryptic 
cleavage in the crosslinked complex at positions 
K56-A57, R58-G59, R123-4124, K136-Cl37 
(fig.2). It has been reported that the peptidic chain 
at arginines 44 and 58 is easily cleaved in the free 
EF-Tu by trypsin even under limited digestion con- 
ditions, with a concomitant loss of aminoacyl- 
tRNA binding activity [18,19]. The high resistance 
to the tryptic cleavage at Arg 58 within the com- 
plex suggests that this area is protected by the close 
neighbourhood of the tRNA. Indeed, after rever- 
sion of the crosslink this bond became cleavable 
even by chymotrypsin, as this enzyme itself has 
also some tryptic activity. 
Identification of the above tryptic peptides is 
confirmed by sequencing the peptides generated by 
cleaving the crosslinked EF-Tu/tRNA complex 
with Staphylococcus aureus V8 protease. Three se- 
quences could be identified (see fig.2): two major 
peptides Sla (56-68) and S2a (64-68), and a minor 
one Sb (118-124). S2a is a subfragment of Sla 
which is a part of peptide Ta, whereas Sb is located 
at the N-terminus of peptide Tb. This strongly sug- 
gests that the major crosslinked residue(s) is 
located in fragment 64-68, and the minor one in 
fragment 118-124. Both sequences contain a 
histidine residue (His 66 and His 118) which are 
potential targets for the platination reaction. Com- 
parison of the primary structure of EF-Tu from 
different sources (fig.3) shows that both crosslink- 
ed fragments Ta and Tb exhibit a very high degree 
of homology (70%). It is remarkable to point out 
that both protected histidines 66 and 118 found in 
the ternary complex by the tRNA in other ex- 
periments (see section 1) are conserved in all 
species studied so far. 
The crosslinked peptides are represented on the 
three-dimensional structure model of EF-Tu pro- 
posed by Nyborg and La Cour [20] (fig.4). Sum- 
marizing all the biochemical data dealing with the 
45 50 (y) 60 66 70 74 
Ta:AFDQIDNAPEdARGITINTSHVEYDTPTR + 
I Ta I _-------- 
,Cla~C2a~c3a c4a c5a, ---- -w-v _-__ __-_ 
,-Sla I WV__ 
-S2a- -_- 
117118 120 130 140 150 154 
Tb:ERILLGRQVGVPYIIVFLNKCDMVDDEELLELVEMEVR 
&lb_CZb ,_C3bpC4b+C5bc64_C7ba CSb_+C9b~lOb,_Cllb_+C12b, 
--- -_- --- .-.-_-..- -- -- _- 
1 Sb- .-v-w 
Fig.2. Amino acid sequences of the EF-Tu regions crosslinked to the RNA. (-) Amino acid determined by automated Edman 
degradation. Residues are noted by the one-letter abbreviation system. T, tryptic peptides; C, chymotryptic peptides; S, S. uureus V8 
protease peptides. 0) Cleavage by limited tryptic digestion. 
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117 154 
Fig.3. Sequence comparison of the two tryptic peptides 45-74 and 117-154 from E. coli (I) EF-Tu crosslinked to the tRNA with EF-Tu 
sequences from Euglena grociffs chloroplast (2) [28], Succharomyces cerevbiue mitochondria (3) [29] and Thermus thermophffus (4) 
[30]. Homologous areas are boxed. 
protection of the amino acid residues by the tRNA 
(see section 1) and with the crosslinking data, it is 
striking that all these residues are exclusively 
located in domains I and II (His 66 and 118, Cys 
81, Lys 2, 4, 208, 237, 248, 263, 282). 
In a previous paper [I 11, we have identified two 
Fig.4. Location on the three-dimensional structure model of EF-Tu proposed by Nyborg and La Cow [ZO] of the shortest crossfinked 
peptides 64-68 and 118-124 (dashed boxes). (I) The different tryptic and S. c?ureu.s V8 protease cleavages. 
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Tl oligonucleotides crosslinked to EF-Tu in the 
ternary complex by trans-DDP, a major one 
located in the 3 ’ -strand of the T-stem in which G65 
would be the residue involved in the crosslinking 
reaction, and a minor one encompassing the an- 
ticodon region in which the crosslinking 
presumably occurred at G43 or G45 at the 3 ‘-end 
of the anticodon stem. A stereoscopic view of 
tRNAPhc showed that the 3 ‘-part of both 
crosslinked regions is located on the same side of 
the tRNA [ 111. This suggests a model of interac- 
tion in which the L-shaped tRNA lies parallel onto 
the protein as already proposed by Kabsch‘ et al. 
[21]. This model provides large surface contacts as 
supported by the high-binding constants [22,23] 
and by the protection of tRNA against nuclease 
digestion in the complex (for a review see [24]). If 
we assume that the major crosslinked peptide 
(residues 56-68 or even 64-68) is linked to the ma- 
jor crosslinked Tl fragment (nucleotides 58-65), 
one can postulate that the potential crosslinking 
residue in this peptide is His 66 which would be 
separated by a 7 A distance (length of trans-DDP) 
from the postulated G65. His 66 was already found 
to be protected by aminoacyl-tRNA and crosslink- 
ed to the chemically modified amino acid of the 
aminoacyl-tRNA [5]. This would also fit with the 
location of the 3 ’ -end of the tRNA near the GDP- 
binding site [24]. In this arrangement, the 
3 ‘-strand of the amino acid- and T-stems are in 
contact with EF-Tu but not the T-loop. This orien- 
tation is also consistent with the footprinting ex- 
periments [24]. However, this localization of the 
3 ‘-end of the tRNA is not in agreement with the 
crosslinking of the 3 ’ -oxidized tRNA to lysines 208 
and 237 in the presence of kirromycin [6,7]. As for 
the second minor crosslinking site (peptide 
118-124), the candidate for the platination is His 
118. Indeed His 118 was also found to be protected 
by the tRNA [4]. The crosslinking of His 118 with 
G43 or G45 would also fit with the crosslinking 
data of Kao et al. [25] who crosslinked nucleotide 
47 in the extra arm of E. coli Phe-tRNAPhe with a 
20 A bridging reagent to EF-Tu. However, multi- 
ple orientations of the anticodon arm with respect 
to EF-Tu remain possible, especially if one would 
conciliate these results with the protection of the 
lysines in domain II mentioned in section 1, the 
footprinting data, small X-ray and small-angle 
scattering studies [26,27] which suggested that the 
anticodon loop would be protruding from the pro- 
tein. Experiments are presently in progress to 
isolate the crosslinked oligonucleotide-peptide 
fragments in order to identify those residues that 
are involved in the crosslinking reaction. This 
would greatly help in the correct positioning of the 
tRNA on EF-Tu within the ternary complex. 
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